AYTU | Aytu BioPharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5000 - 1.6300
52 Week Range	1.4100 - 3.45
Beta	0.13
Implied Volatility	563.69%
IV Rank	57.24%
Day's Volume	27,266
Average Volume	29,079
Shares Outstanding	6,149,370
Market Cap	10,023,473
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2008-09-25

Valuation
Profitability
Growth
Health
P/E Ratio	-0.96
Forward P/E Ratio	N/A
EPS	-1.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	102
Country	USA
Website	AYTU

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments BioPharma and Consumer Health segments of which it generates maximum revenue from the BioPharma segment.

AYTU's peers: AQST, EVOK, ADMP, GHSI, ACRX, SGIOY, SBFM, ALIM, SXTC, SHPH, LFCR, PTPI, IRWD, NEPT, FLGC, JUPW, SNOA, ESPR, DERM, AVDL

*Chart delayed

Analyzing fundamentals for AYTU we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see AYTU Fundamentals page.

Watching at AYTU technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AYTU Technicals page.